Cas12 Protein Market Report 2025

The Cas12 protein market size has grown rapidly in recent years. It will grow from $1.95 billion in 2024 to $2.26 billion in 2025 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to rising government investments in biotechnology and genetic engineering initiatives, increasing demand for point-of-care diagnostic solutions in developing regions, expanding integration of Cas12 systems into next-generation sequencing platforms, heightened focus on early disease detection and prevention strategies, and advancing protein engineering techniques that improve Cas12 specificity.

The Cas12 protein market size is expected to see rapid growth in the next few years. It will grow to $4.03 billion in 2029 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to the rising prevalence of genetic disorders, increasing investment in gene-editing research and development, growing awareness of personalized medicine, higher demand for rapid and precise infectious disease diagnostics, and expanding use of Cas12 proteins in agricultural biotechnology for crop enhancement. Key trends in the forecast period include integration with other CRISPR components, advancements in gene-editing delivery technologies, development of modified Cas12 proteins, technological improvements in diagnostic platforms, and progress in bioinformatics tools.

The rising prevalence of genetic diseases is expected to drive the growth of the Cas12 protein market in the coming years. Genetic diseases are caused by mutations or changes in an individual's DNA that disrupt normal bodily functions. Their increasing incidence is linked to the rising rate of consanguineous marriages, which heightens the likelihood of inheriting genetic disorders. Cas12 proteins precisely target and cut DNA at specific sites to correct, remove, or replace faulty genes, enabling highly accurate gene therapies for inherited conditions with minimal off-target effects. For example, in May 2024, the National Health Service, a UK-based government department, reported that approximately 17,000 people in England live with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed annually. Consequently, the growing prevalence of genetic diseases is fueling demand in the Cas12 protein market.

Key companies in the Cas12 protein market are adopting strategic approaches, such as equity investments, to accelerate innovation and expand gene-editing capabilities. Equity investment involves purchasing shares or ownership stakes in a company, giving investors partial ownership and potential returns based on company performance. For instance, in April 2024, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, invested $100 million in Mammoth Biosciences to access their ultracompact CRISPR enzymes for in vivo gene editing therapies using adeno-associated viruses (AAVs) across multiple tissues beyond the liver. By combining Mammoth’s ultracompact CRISPR enzymes with Regeneron’s advanced AAV delivery system, the partnership enables precise and efficient in vivo editing. This collaboration provides Mammoth with funding, milestones, and royalties, while Regeneron gains exclusive access to advanced gene-editing tools for over five years, collectively accelerating next-generation genetic medicines for a broader range of diseases.

In August 2023, Hui-Gene Therapeutics Co., Ltd., a China-based biotechnology company, partnered with Kactus Biotechnology to develop novel gene-editing therapies targeting rare genetic disorders. The collaboration aims to fast-track commercialization and GMP manufacturing of Hui-Gene’s high-precision gene-editing enzyme hfCas12Max in Greater China, leveraging Kactus Bio’s expertise to advance next-generation genome medicines. Kactus Biotechnology is a China-based company specializing in the production of Cas12 proteins.

Major players in the cas12 protein market are Thermo Fisher Scientific Inc., Bio-Techne Corporation, Integrated DNA Technologies Inc., GenScript Biotech Corporation, Takara Bio Inc., Abcam plc, Aldevron LLC, New England Biolabs Inc., Cusabio Biotech Co. Ltd., Synthego Corporation, ABclonal Technology Co. Ltd., Mammoth Biosciences Inc., Rockland Immunochemicals Inc., Creative BioMart, Editas Medicine Inc., VectorBuilder, Sherlock Biosciences, Biomatik, SBS Genetech Co. Ltd., ProSpec-Tany Technogene Ltd., Inscripta Inc., Addgene Inc.

North America was the largest region in the Cas12 protein market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in Cas12 protein market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Cas12 protein market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Cas12 protein is an enzyme associated with clustered regularly interspaced short palindromic repeats (CRISPR) that plays a crucial role in gene editing and molecular diagnostics. Guided by CRISPR RNA, Cas12 locates specific DNA sequences and cleaves them precisely, allowing for targeted genetic modifications. Its collateral cleavage activity also makes it valuable for rapid and sensitive diagnostic applications.

The primary types of Cas12 protein include natural Cas12 proteins, modified Cas12 proteins, and those integrated with other CRISPR components. Natural Cas12 proteins are bacterial enzymes that identify and cut specific DNA sequences as part of the CRISPR immune defense system. These proteins are available in different formulations, such as liquid, lyophilized powder, and plasmid-derived forms. Common delivery methods include viral vectors, lipid nanoparticles, electroporation, and microinjection. Cas12 proteins are widely used in applications such as genome editing, gene knockout, gene regulation, genetic engineering, and therapeutic development, serving end users including academic and research institutions, pharmaceutical and biotechnology companies, diagnostic laboratories, and agricultural organizations.

The Cas12 protein market research report is one of a series of new reports that provides Cas12 protein market statistics, including Cas12 protein industry global market size, regional shares, competitors with a Cas12 protein market share, detailed Cas12 protein market segments, market trends and opportunities, and any further data you may need to thrive in the Cas12 protein industry. This Cas12 protein market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The Cas12 protein market consists of sales of molecular diagnostic kits, research reagents, and biosensors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.